One-year real-life outcomes of lanadelumab therapy in Romanian patients with hereditary angioedema due to C1-inhibitor deficiency
IntroductionIn the majority of patients with hereditary angioedema (HAE) due to C1-inhibitor deficiency (HAE-C1INH), effective long-term prophylactic (LTP) treatment can achieve complete disease control. Lanadelumab is one of the first-line option recommended for this purpose. Our study aimed to eva...
Saved in:
| Main Authors: | Noémi Anna Bara, Valentin Nădășan, Diana Deleanu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Allergy |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/falgy.2025.1636425/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A single-centre retrospective study on the clinical characteristics of patients with hereditary angioedema and the therapeutic effect of lanadelumab
by: Yanhua Xu, et al.
Published: (2025-08-01) -
The determinants of angioedema attacks related to dental and gingival procedures in hereditary angioedema patients
by: Nihal M. Gokmen, et al.
Published: (2025-07-01) -
Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema
by: Sarah Walsh, et al.
Published: (2025-07-01) -
Recurrent angioedema manifestation and treatment response in two patients from different families caring the myoferlin gene mutation: case series
by: Daria S. Fomina, et al.
Published: (2025-08-01) -
Bradykinin measurement by liquid chromatography tandem mass spectrometry in subjects with hereditary angioedema enhanced by cold activation
by: Jinguo Chen, MD, et al.
Published: (2025-08-01)